Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
daunorubicin and cytarabine liposome (Jazz Pharmaceuticals plc, 041b46)
- Development stage
- Phase 4
- Lead developer
- Jazz Pharmaceuticals
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
CPX-351 (Vyxeos) is a liposomal formulation of the cytotoxic agents daunorubicin and cytarabine, encapsulated at a fixed 1:5 molar ratio. This specific ratio was identified in preclinical studies to maximize synergistic antileukemic activity. The liposomal delivery system optimizes the pharmacokinetics of the two drugs, prolonging their half-life and enhancing their accumulation and persistence within the bone marrow. Cytarabine is a pyrimidine analog that inhibits DNA synthesis by competing with dCTP for incorporation into DNA and inhibiting DNA polymerase. Daunorubicin is an anthracycline that intercalates into DNA and inhibits topoisomerase II, leading to DNA strand breaks and apoptosis. Developed by Celator Pharmaceuticals (acquired by Jazz Pharmaceuticals), CPX-351 is primarily indicated for the treatment of adults and pediatric patients with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
- Brand names
- Vyxeos
- Other names
- liposomal cytarabine and daunorubicincytarabine-daunorubicin liposomedaunorubicin + cytarabine liposome
02
Targets
DNAPOLA1 (DNA polymerase alpha)TOP2A (DNA topoisomerase II)TOP2B (DNA topoisomerase II beta)
Beyond the preview
Go deeper on daunorubicin and cytarabine liposome (Jazz Pharmaceuticals plc, 041b46).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on daunorubicin and cytarabine liposome (Jazz Pharmaceuticals plc, 041b46).